Author: admin

Despite traditionally being excluded from systemic therapy trials, patients with moderate psoriasis—defined as having Body Surface Area (BSA) of 3% to 10% or involvement of high-impact areas—are now recognized as eligible under the International Psoriasis Council’s (IPF’s) updated classification.¹ A study of real-world data demonstrated that 12 months of risankizumab treatment led to substantial skin clearance and quality of life improvements in this previously underrepresented group.

This retrospective study is published in Dermatology and Therapy.

“After 12 months of continuous treatment with risankizumab, all patient groups evaluated in this study showed significant improvements in their PASI [Psoriasis Area Severity Index] scores,” wrote the researchers of the study. “The majority achieved NPF [National Psoriasis Foundation] treat-to-target goals and had significant improvement in quality of life, psoriasis symptoms, and reduced work and activity impairment.”

Although psoriasis treatment guidelines have historically focused on patients with BSA involvement greater than 10%, growing evidence highlights that individuals with BSA of 3% or less can experience a disease burden comparable to those with more extensive skin involvement.² Data from the CorEvitas Psoriasis Registry show that patient-reported outcomes (PROs) related to itch, pain, fatigue, and quality of life significantly overlap across low, medium, and high BSA categories.

This analysis utilized data from the CorEvitas Psoriasis Registry to evaluate real-world outcomes in biologic-naïve adults with moderate to severe plaque psoriasis who initiated risankizumab treatment between April 2019 and August 2023.¹ Eligible patients received continuous risankizumab therapy for 12 months and were stratified by baseline BSA: 3% to 10% or greater than 10%.

Within the BSA 3% to 10% subgroup, patients were further assessed for involvement of high-impact areas and prior use of topical therapy, aligning with the IPF criteria for systemic therapy eligibility. Effectiveness outcomes included achievement of Psoriasis Area and Severity Index (PASI) 90 and 100 and National Psoriasis Foundation (NPF) treat-to-target goals. PROs included the proportion achieving a Dermatology Life Quality Index (DLQI) score of 0/1, as well as changes in symptom burden and work or activity impairment from baseline.

Among the 272 patients included in the analysis, 123 had baseline BSA between 3% and 10%, of whom 78 had psoriasis in high-impact areas and 105 had a history of topical therapy use, meeting IPC criteria for systemic eligibility. The remaining 149 patients had BSA greater than 10%. In the BSA 3% to 10% group, 77.9% achieved PASI 90 and 67.2% achieved PASI 100 after 12 months of risankizumab treatment. Additionally, 95.3% met the NPF’s acceptable target, and 87.9% reached the optimal target.

PROs were similarly encouraging, with 68.1% achieving a DLQI score of 0/1, indicating minimal impact on quality of life. Statistically significant improvements were also observed in psoriasis symptom burden and reductions in both work and activity impairment (P < .001). Furthermore, comparable clinical and quality of life benefits were seen across all IPC-defined subgroups, supporting the effectiveness of risankizumab in patients beyond traditional systemic therapy thresholds.

However, the researchers noted several limitations. Although safety outcomes were not evaluated, prior clinical trials have demonstrated a favorable long-term safety profile for risankizumab. Ongoing studies (EUPAS3935; NCT04799990) aim to assess the real-world safety of risankizumab more comprehensively. Additionally, the current analysis was limited by the absence of head-to-head comparisons with other biologic or systemic therapies in patients newly classified as systemic-eligible under IPC guidelines. The lack of comparable real-world studies for alternative treatments also limited these findings.

Despite these limitations, the researchers believe the study provides evidence that supports risankizumab in patients eligible for systemic therapy under IPC guidelines.

“Given these outcomes, risankizumab may be considered a primary systemic therapy option for treating patients eligible for systemic therapy,” wrote the researchers.

References

1. Strober B, Patel M, Kaldas MI, et al. Real-world skin clearance and quality of life with risankizumab in patients with psoriasis with moderate skin involvement and those eligible for systemic therapy per International Psoriasis Council classification. Dermatol Ther (Heidelb). Published online July 2, 2025. doi:10.1007/s13555-025-01474-3

2. Steinzor P. Low BSA in psoriasis may still mean high disease burden. AJMC^®. June 12, 2025. Accessed July 2, 2025. https://www.ajmc.com/view/low-bsa-in-psoriasis-may-still-mean-high-disease-burden

July 8, 2025

PRESS RELEASE

Apple announces chief operating officer transition

CUPERTINO, CALIFORNIA Apple today announced Jeff Williams will transition his role as chief operating officer later this month to Sabih Khan, Apple’s senior vice president of Operations, as part of a long-planned succession. Williams will continue reporting to Apple CEO Tim Cook and overseeing Apple’s world-class design team and Apple Watch alongside the company’s Health initiatives. Apple’s design team will then transition to reporting directly to Cook after Williams retires late in the year.

“Jeff and I have worked alongside each other for as long as I can remember, and Apple wouldn’t be what it is without him. He’s helped to create one of the most respected global supply chains in the world; launched Apple Watch and overseen its development; architected Apple’s health strategy; and led our world-class team of designers with great wisdom, heart, and dedication,” said Tim Cook, Apple’s CEO. “I am and will always be beyond grateful for his numerous contributions to Apple over the years and his loyal friendship. Jeff’s true legacy can be seen in the amazing team he’s created and, while he’ll be greatly missed, he leaves the work of the future in incredible hands.”

“Sabih is a brilliant strategist who has been one of the central architects of Apple’s supply chain,” said Tim Cook, Apple’s CEO. “While overseeing Apple’s supply chain, he has helped pioneer new technologies in advanced manufacturing, overseen the expansion of Apple’s manufacturing footprint in the United States, and helped ensure that Apple can be nimble in response to global challenges. He has advanced our ambitious efforts in environmental sustainability, helping reduce Apple’s carbon footprint by more than 60 percent. Above all, Sabih leads with his heart and his values, and I know he will make an exceptional chief operating officer.”

Khan has been at Apple for 30 years and joined the executive team as senior vice president of Operations in 2019. He has been in charge of Apple’s global supply chain for the past six years, ensuring product quality and overseeing planning, procurement, manufacturing, logistics, and product fulfillment functions, as well as Apple’s supplier responsibility programs that protect and educate workers at production facilities around the world. The team also supports Apple’s environmental initiatives by partnering with suppliers to propel green manufacturing, helping conserve resources and protect the planet.

During his career with Apple, Williams built out a supply chain that has supported Apple’s growth and customers around the world with expansion, including the United States, China, India, Japan, and across Southeast Asia. He led Apple’s supplier responsibility efforts which has helped raise the bar for workers around the world, offering critical training and important education programs. Williams played a key role in the introduction of iPod and iPhone programs. He led the effort on Apple Watch over a decade ago and architected the company’s health strategy, helping customers live healthier lives, learn more about their health, and receive lifesaving care. For the past several years, Williams has also overseen Apple’s industry-leading design team.

“I have a deep love for Apple. Working with all of the amazing people at this company has been a privilege of a lifetime, and I can’t thank Tim enough for the opportunity, his inspirational leadership, and our friendship over the years,” said Williams. “June marked my 27th anniversary with Apple, and my 40th in the industry. Beginning next year, I plan to spend more time with friends and family, including five grandchildren and counting. I’ve had the pleasure of working closely with Sabih for 27 years and I think he’s the most talented operations executive on the planet. I have tremendous confidence in Apple’s future under his leadership in this role.”

Before joining Apple’s procurement group in 1995, Khan worked as an applications development engineer and key account technical leader at GE Plastics. He earned bachelor’s degrees in economics and mechanical engineering from Tufts University and a master’s degree in mechanical engineering from Rensselaer Polytechnic Institute.

About Apple
Apple revolutionized personal technology with the introduction of the Macintosh in 1984. Today, Apple leads the world in innovation with iPhone, iPad, Mac, AirPods, Apple Watch, and Apple Vision Pro. Apple’s six software platforms — iOS, iPadOS, macOS, watchOS, visionOS, and tvOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay, iCloud, and Apple TV+. Apple’s more than 150,000 employees are dedicated to making the best products on earth and to leaving the world better than we found it.

Press Contact

Josh Rosenstock

Apple

jrosenstock@apple.com

Investor Relations Contact

Suhasini Chandramouli

Apple

suhasini@apple.com

(408) 974-3123

© 2025 Apple Inc. All rights reserved. Apple and the Apple logo are trademarks of Apple. Other company and product names may be trademarks of their respective owners.

LEXINGTON, Ky., July 8, 2025 /PRNewswire/ — Ramaco Resources, Inc. (NASDAQ: METC, METCB) (“Ramaco” or the “Company”) announces that on July 9 it will receive the Preliminary Economic Assessment (the “PEA”) of Ramaco’s Brook Mine from the Fluor Corporation.  The PEA will be presented to the Ramaco Board of Directors (the “Board”) at its Board meeting tomorrow.  Following Fluor’s presentation to the Board and the Board’s opportunity to review,  Ramaco expects to release a summary of the updated information to its website this week. 

About Ramaco Resources, Inc.

Ramaco Resources, Inc. is an operator and developer of high-quality, low-cost metallurgical coal in southern West Virginia, and southwestern Virginia and a developing producer of coal, rare earth and critical minerals in Wyoming. Its executive offices are in Lexington, Kentucky, with operational offices in Charleston, West Virginia and Sheridan, Wyoming.  The Company currently has four active metallurgical coal mining complexes in Central Appalachia and one coal mine and rare earth development near Sheridan, Wyoming in the initial stages of production. In 2023, the Company announced that a major deposit of primary magnetic rare earths and critical minerals was discovered at its mine near Sheridan, Wyoming.  Contiguous to the Wyoming mine, the Company operates a carbon research and pilot facility related to the production of advanced carbon products and materials from coal. In connection with these activities, it holds a body of roughly 76 intellectual property patents, pending applications, exclusive licensing agreements and various trademarks. News and additional information about Ramaco Resources, including filings with the Securities and Exchange Commission, are available at https://www.ramacoresources.com. For more information, contact investor relations at (859) 244-7455.

Point of Contact:
INVESTOR RELATIONS:
[email protected]
or 859-244-7455

SOURCE Ramaco Resources, Inc.